ReviewHepatology international2019
Reversal of NASH fibrosis with pharmacotherapy.
Review in Hepatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Emerging nanomedicine for liver diseases treatment.Journal of nanobiotechnology · 2025Review
- Immunological dynamics in MASH: from landscape analysis to therapeutic intervention.Journal of gastroenterology · 2024Review
- Growth hormone and nonalcoholic fatty liver disease.Immunometabolism (Cobham, Surrey) · 2023 · on this mapReview
- Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2023Review
- New Drugs for Hepatic Fibrosis.Frontiers in pharmacology · 2022Review
- Therapeutic potentials of fasudil in liver fibrosis.World journal of gastroenterology · 2021Article
- MR Elastography of the Abdomen: Basic Concepts.Methods in molecular biology (Clifton, N.J.) · 2021Article
- MR Elastography of the Abdomen: Experimental Protocols.Methods in molecular biology (Clifton, N.J.) · 2021Article
- NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States.Journal of clinical and translational hepatology · 2020Review
- NAFLD Preclinical Models: More than a Handful, Less of a Concern?Biomedicines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NAFLD is a spectrum of liver disease starting with fatty liver at one end of the spectrum and cirrhosis or liver cancer at the other end. Worldwide, NAFLD has become one of the most common liver diseases and it has also become one of the leading indications for liver transplantation. Our understanding of the NAFLD epidemiology, pathogenesis and its progression to cirrhosis has improved over the last 2 decades. Currently, however, there are no FDA-approved treatment options for fibrosis resulting from NAFLD. A number of compounds targeting multiple pathways involved in the progression of NAFLD are currently in phase 2-3 trials. In this review, we will briefly discuss the epidemiology, the pathogenesis and the current status of treatment of NAFLD.
Indexed as
Identifiers
31363910What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.